Infantile Hemangioma

Martínez, María Isabel López

doi:10.1001/archderm.138.7.881

Cited by 95 publications

(13 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The application site reactions were widely accepted as a required sign of therapeutic response rather than of toxicity (Martinez et al, 2002;Sidbury et al, 2003;Welsh et al, 2004;Hazen et al, 2005;Barry et al, 2008). In this study, most low-responders showed relative minimal inflammation, which appeals the theory that the lack of clinical efficacy correlates to an insufficient inflammatory reaction.…”

Section: Discussionmentioning

confidence: 85%

“…Since the first report in 2002 that showed the potential of imiquimod in accelerating the regression of IH (Martinez et al, 2002), continuous efforts have been made to investigate the role and potential toxicities of imiquimod in the treatment of cutaneous vascular disorders (Sidbury et al, 2003;Welsh et al, 2004;Hazen et al, 2005;Sanchez-Carpintero et al, 2006;Ho et al, 2007;Barry et al, 2008). A variety of mechanisms might be involved in imiquimodinduced regression of vascular tumors (SanchezCarpintero et al, 2006), including an immune response (Sun et al, 2007).…”

Section: Discussionmentioning

confidence: 99%

“…Early intervention may limit some sequelaes such as ulcerations and tissue necrosis during the fast proliferating phase, or residual skin changes after spontaneous involution (Welsh et al, 2004). Several American and European reports have suggested the efficacy and safety of the topical application of imiquimod in the treatment of IHs (Martinez et al, 2002;Welsh et al, 2004;Hazen et al, 2005;Ho et al, 2007;Barry et al, 2008;McCuaig et al, 2009). In this report, 25 Chinese pediatric patients with various cutaneous vascular disorders were treated with topical imiquimod and evaluated for the therapeutic response and tolerability.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Topical imiquimod treatment of cutaneous vascular disorders in pediatric patients: clinical evaluation on the efficacy and safety

Mao¹,

Wang²,

Yan³

2012

J. Zhejiang Univ. Sci. B

View full text Add to dashboard Cite

Abstract:Objective: To evaluate the clinical effect of topical imiquimod treatment on cutaneous vascular disorders in pediatric patients. Methods: A retrospective investigation was conducted in 25 pediatric patients with cutaneous vascular disorders, including 19 infantile hemangiomas (IHs) (12 superficial/7 mixed type), 5 nevus flammeus (NF), and 1 pyogenic granuloma (PG). Imiquimod 5% cream was applied every other day for 4 to 16 weeks (average 9.6 weeks). Results: Of the 19 IHs treated, an overall efficacy of 52.6% was achieved, with a clinical resolution rate of 15.8%, excellent rate of 26.3%, and moderate rate of 10.5%. The superficial type responded the best at 66.7%, while the mixed type showed only 28.6% effectiveness, which was predominantly from their superficial parts. No obvious response was noted in the 5 patients with NF. Side effects were observed in 78.9% of the patients, mostly mild to moderate local irritations and occasionally severe reactions such as thick crusting and ulceration. Systemic side events were observed in 4 IH patients including fever and digestive tract reactions. No recurrence was observed during the follow-up examination. Conclusions: Topical imiquimod could be an alternative option for the treatment of uncomplicated superficial IHs with satisfactory tolerability.

show abstract

Section: Discussionmentioning

confidence: 85%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Topical imiquimod treatment of cutaneous vascular disorders in pediatric patients: clinical evaluation on the efficacy and safety

Mao¹,

Wang²,

Yan³

2012

J. Zhejiang Univ. Sci. B

View full text Add to dashboard Cite

show abstract

“…Topically applied imiquimod is currently approved by the US FDA for treatment of warts and non-melanoma skin cancer, and is an experimental agent for treatment of melanoma [11][12][13][14][15][16][17]. Topical imiquimod is also an effective treatment for infantile hemangiomas [18][19][20] and can inhibit vascular development in tumors [21]. In a case of melanoma metastases, treatment with imiquimod was demonstrated to alter transcription of several molecules involved in regulation of angiogenesis and metastasis [11].…”

Section: Introductionmentioning

confidence: 99%

Anti-Cancer Activities and Interaction of Imiquimod and Flex-Het, SHetA2, in Melanoma and Ovarian Cancer

Naylor¹,

Thompson²,

Lightfoot³

et al. 2013

JCT

View full text Add to dashboard Cite

New strategies are needed to treat cancers that do not respond to chemotherapy or resist chemotherapy after responding initially. The objective of this study was to evaluate non-cytotoxic drugs against two of these cancers, melanoma and ovarian cancer. Imiquimod is an immune stimulant that induces apoptosis in cancer cells. Flexible-Heteroarotinoids (Flex-Hets) are small molecules that regulate growth, differentiation and apoptosis in cancer cells with reduced effects on normal cells. Both imiquimod and SHetA2 inhibited growth and induced apoptosis in the B16 melanoma cell line and cisplatin-sensitive A2780 and cisplatin-resistant OVCAR-3 ovarian cancer cell lines. The growth inhibition was additive in A2780 and B16, and synergistic in OVCAR-3. Both compounds inhibited endothelial tube branching in vitro and exerted an additive effect when combined. Various combinations of imiquimod and SHetA2 did not cause significant differences in the overall survival in the syngeneic B16 murine melanoma model. SHetA2 induced complete tumor regression and a melanoma-free natural life-span in two mice. These cures occurred in one of ten mice treated with oral SHetA2 and one of ten mice intratumorally-injected with SHetA2. Exploratory modeling of the distribution of survival times suggested that the two surviving mice represent rare events. Histologic evaluation of the tumors revealed that imiquimod induced necrosis, SHetA2 induced differentiated architecture and increased cytoplasm, both agents reduced mitotic indices and angiogenesis and neither agent counteracted the effects of the other. No overt toxicities were observed. In conclusion, imiquimod and SHetA2 exhibit complementary anti-cancer activity in vitro and SHetA2 has promise as a single agent.

show abstract

“…Imiquimod is primarily used to treat genital warts [5]. Also imiquimod cream has recently been reported to be effective in managing infantile hemangiomas [6,7,8]. We present an ALHE case who was successfully treated by using topical imiquimod cream, which is a nondestructive and cosmetic therapy.…”

Section: Introductionmentioning

confidence: 99%

Angiolymphoid Hyperplasia with Eosinophilia Successfully Treated with Imiquimod

2007

View full text Add to dashboard Cite

Angiolymphoid hyperplasia with eosinophilia (ALHE) is a rare disorder characterized by vascular proliferation, eosinophilia in peripheral blood samples and lymphocytosis. The etiology is unknown; this rare condition is generally seen in women. It often presents as multiple, grouped red nodules in the periauricular region, scalp line and neck. Numerous therapeutic approaches have been tried for ALHE including destructive techniques such as electrodesiccation, cryotherapy, surgical excision, radiotherapy or laser (argon, CO₂, pulse dye). We present an ALHE case that was treated successfully by using topical imiquimod cream.

show abstract

Infantile Hemangioma

Cited by 95 publications

References 14 publications

Topical imiquimod treatment of cutaneous vascular disorders in pediatric patients: clinical evaluation on the efficacy and safety

Topical imiquimod treatment of cutaneous vascular disorders in pediatric patients: clinical evaluation on the efficacy and safety

Anti-Cancer Activities and Interaction of Imiquimod and Flex-Het, SHetA2, in Melanoma and Ovarian Cancer

Angiolymphoid Hyperplasia with Eosinophilia Successfully Treated with Imiquimod

Contact Info

Product

Resources

About